The DOI matches its Crossref record; 206 of the 206 references it cites were found in a registry or an index.
The Promise of Nanotechnology in Personalized Medicine
Open accessAbstract
Both personalized medicine and nanomedicine are new to medical practice. Nanomedicine is an application of the advances of nanotechnology in medicine and is being integrated into diagnostic and therapeutic tools to manage an array of medical conditions. On the other hand, personalized medicine, which is also referred to as precision medicine, is a novel concept that aims to individualize/customize therapeutic management based on the personal attributes of the patient to overcome blanket treatment that is only efficient in a subset of patients, leaving others with either ineffective treatment or treatment that results in significant toxicity. Novel nanomedicines have been employed in the treatment of several diseases, which can be adapted to each patient-specific case according to their genetic profiles. In this review, we discuss both areas and the intersection between the two emerging scientific domains. The review focuses on the current situation in personalized medicine, the advantages that can be offered by nanomedicine to personalized medicine, and the application of nanoconstructs in the diagnosis of genetic variability that can identify the right drug for the right patient. Finally, we touch upon the challenges in both fields towards the translation of nano-personalized medicine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zwischenmolekulare Energiewanderung und Fluoreszenz
Förster, T. (1948) · Annalen der Physik · doi:10.1002/andp.19484370105 · Cited by 8,285
Engineering precision nanoparticles for drug delivery
Mitchell, M. J., Billingsley, M. M., Haley, R. M., Wechsler, M. E., Peppas, N. A., & Langer, R. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0090-8 · Cited by 7,933
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00248-5 · Cited by 6,565 · cited 1×
“[23] that allows a more specific drug accumulation in solid tumors and in infection sites [24].”
Quantum dot bioconjugates for imaging, labelling and sensing
Medintz, I. L., Uyeda, H. T., Goldman, E. R., & Mattoussi, H. (2005) · Nature Materials · doi:10.1038/nmat1390 · Cited by 6,229
Drug delivery and nanoparticles: Applications and hazards
de Jong (2008) · International Journal of Nanomedicine · doi:10.2147/ijn.s596 · Cited by 3,848
Tumour stem cells and drug resistance
Dean, M., Fojo, T., & Bates, S. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1590 · Cited by 3,668
Molecular mechanism and physiological functions of clathrin-mediated endocytosis
McMahon, H. T., & Boucrot, E. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3151 · Cited by 2,223
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
Sun, T., Zhang, Y. S., Pang, B., Hyun, D. C., Yang, M., & Xia, Y. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201403036 · Cited by 2,164
Towards a definition of inorganic nanoparticles from an environmental, health and safety perspective
Auffan, M., Rose, J., Bottero, J.-Y., Lowry, G. V., Jolivet, J.-P., & Wiesner, M. R. (2009) · Nature Nanotechnology · doi:10.1038/nnano.2009.242 · Cited by 1,950
Integrating liquid biopsies into the management of cancer
Siravegna, G., Marsoni, S., Siena, S., & Bardelli, A. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.14 · Cited by 1,908
Nanomedicine in cancer therapy: Challenges, opportunities, and clinical applications
Wicki, A., Witzigmann, D., Balasubramanian, V., & Huwyler, J. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.12.030 · Cited by 1,901
Sotorasib for Lung Cancers with KRAS p.G12C Mutation
Skoulidis, F., Li, B. T., Dy, G. K., Price, T. J., Falchook, G. S., Wolf, J., Italiano, A., Schuler, M., Borghaei, H., Barlesi, F., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103695 · Cited by 1,849
Tumor microenvironment and therapeutic response
Wu, T., & Dai, Y. (2017) · Cancer Letters · doi:10.1016/j.canlet.2016.01.043 · Cited by 1,802
Mechanisms of Multidrug Resistance in Cancer Chemotherapy
Bukowski, K., Kciuk, M., & Kontek, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093233 · Cited by 1,757
The entry of nanoparticles into solid tumours
Sindhwani, S., Syed, A. M., Ngai, J., Kingston, B. R., Maiorino, L., Rothschild, J., MacMillan, P., Zhang, Y., Rajesh, N. U., Hoang, T., et al. (2020) · Nature Materials · doi:10.1038/s41563-019-0566-2 · Cited by 1,732
Airway Mucus Function and Dysfunction
Fahy, J. V., & Dickey, B. F. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0910061 · Cited by 1,722
Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo
Farokhzad, O. C., Cheng, J., Teply, B. A., Sherifi, I., Jon, S., Kantoff, P. W., Richie, J. P., & Langer, R. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601755103 · Cited by 1,663
Oral drug delivery with polymeric nanoparticles: The gastrointestinal mucus barriers
Ensign, L. M., Cone, R., & Hanes, J. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.12.009 · Cited by 1,623
Key principles and methods for studying the endocytosis of biological and nanoparticle therapeutics
Rennick, J. J., Johnston, A. P. R., & Parton, R. G. (2021) · Nature Nanotechnology · doi:10.1038/s41565-021-00858-8 · Cited by 1,477
Cone, R. A. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.09.008 · Cited by 1,459
Insoluble drug delivery strategies: review of recent advances and business prospects
Kalepu, S., & Nekkanti, V. (2015) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2015.07.003 · Cited by 1,410
van der Meel, R., Sulheim, E., Shi, Y., Kiessling, F., Mulder, W. J. M., & Lammers, T. (2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0567-y · Cited by 1,234
Fleige, E., Quadir, M. A., & Haag, R. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.01.020 · Cited by 1,111
Hua, S., de Matos, M. B. C., Metselaar, J. M., & Storm, G. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00790 · Cited by 1,048
Cancer stem cells—Origins and biomarkers: Perspectives for targeted personalized therapies
Walcher, L., Kistenmacher, A.-K., Suo, H., Kitte, R., Dluczek, S., Strauß, A., Blaudszun, A.-R., Yevsa, T., Fricke, S., & Kossatz-Boehlert, U. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01280 · Cited by 1,007
Personalized medicine: motivation, challenges, and progress
Goetz, L. H., & Schork, N. J. (2018) · Fertility and Sterility · doi:10.1016/j.fertnstert.2018.05.006 · Cited by 976
Cell-Penetrating Peptides: Design, Synthesis, and Applications
Copolovici, D. M., Langel, K., Eriste, E., & Langel, Ü. (2014) · ACS Nano · doi:10.1021/nn4057269 · Cited by 963
Concepts of nanoparticle cellular uptake, intracellular trafficking, and kinetics in nanomedicine
Donahue, N. D., Acar, H., & Wilhelm, S. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.04.008 · Cited by 944
Paine, M. F., Khalighi, M., Fisher, J. M., Shen, D. D., Kunze, K. L., Marsh, C. L., Perkins, J. D., & Thummel, K. E. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37149-6 · Cited by 789
Cancer active targeting by nanoparticles: a comprehensive review of literature
Bazak, R., Houri, M., El Achy, S., Kamel, S., & Refaat, T. (2015) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-014-1767-3 · Cited by 756
Bio-Bar-Code-Based DNA Detection with PCR-like Sensitivity
Nam, J.-M., Stoeva, S. I., & Mirkin, C. A. (2004) · Journal of the American Chemical Society · doi:10.1021/ja049384+ · Cited by 744
Nanomedicine therapeutic approaches to overcome cancer drug resistance
Markman, J. L., Rekechenetskiy, A., Holler, E., & Ljubimova, J. Y. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.09.019 · Cited by 733 · cited 2×
“Furthermore, cells who acquire resistance to chemotherapeutic agents usually become resistant also to drugs belonging to different chemical classes or to drugs acting with a different mechanism of action, globally worsening the MDR phenomena [28].”
Stimuli-responsive clustered nanoparticles for improved tumor penetration and therapeutic efficacy
Li, H.-J., Du, J.-Z., Du, X.-J., Xu, C.-F., Sun, C.-Y., Wang, H.-X., Cao, Z.-T., Yang, X.-Z., Zhu, Y.-H., Nie, S., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1522080113 · Cited by 724
Bertrand, N., Grenier, P., Mahmoudi, M., Lima, E. M., Appel, E. A., Dormont, F., Lim, J.-M., Karnik, R., Langer, R., & Farokhzad, O. C. (2017) · Nature Communications · doi:10.1038/s41467-017-00600-w · Cited by 708
Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data
Lee, C. R., Goldstein, J. A., & Pieper, J. A. (2002) · Pharmacogenetics · doi:10.1097/00008571-200204000-00010 · Cited by 686
SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy
Maeda, H. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00134-4 · Cited by 662
Quantifying the Ligand-Coated Nanoparticle Delivery to Cancer Cells in Solid Tumors
Dai, Q., Wilhelm, S., Ding, D., Syed, A. M., Sindhwani, S., Zhang, Y., Chen, Y. Y., MacMillan, P., & Chan, W. C. W. (2018) · ACS Nano · doi:10.1021/acsnano.8b03900 · Cited by 658
Clinical application of pharmacogenetics
Spear, B. B., Heath-Chiozzi, M., & Huff, J. (2001) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(01)01986-4 · Cited by 646
Lin, J., Zhang, H., Chen, Z., & Zheng, Y. (2010) · ACS Nano · doi:10.1021/nn1010792 · Cited by 638
Liang, G., Zhu, Y., Ali, D. J., Tian, T., Xu, H., Si, K., Sun, B., Chen, B., & Xiao, Z. (2020) · Journal of Nanobiotechnology · doi:10.1186/s12951-019-0563-2 · Cited by 619
Ulbrich, K., Hekmatara, T., Herbert, E., & Kreuter, J. (2009) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2008.08.021 · Cited by 591
Bioconjugation of Ultrabright Semiconducting Polymer Dots for Specific Cellular Targeting
Wu, C., Schneider, T., Zeigler, M., Yu, J., Schiro, P. G., Burnham, D. R., McNeill, J. D., & Chiu, D. T. (2010) · Journal of the American Chemical Society · doi:10.1021/ja107196s · Cited by 528
Figuerola, A., Di Corato, R., Manna, L., & Pellegrino, T. (2010) · Pharmacological Research · doi:10.1016/j.phrs.2009.12.012 · Cited by 480
Tat peptide-mediated intracellular delivery of pharmaceutical nanocarriers
Torchilin, V. P. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.10.008 · Cited by 449
Folate-targeted therapies for cancer
Xia, W., & Low, P. S. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100509v · Cited by 448
Lipid-Based Delivery Systems and Intestinal Lymphatic Drug Transport: A Mechanistic Update
Trevaskis, N. L., Charman, W. N., & Porter, C. J. H. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.09.007 · Cited by 442
Biological Identity of Nanoparticles In Vivo : Clinical Implications of the Protein Corona
Caracciolo, G., Farokhzad, O. C., & Mahmoudi, M. (2017) · Trends in Biotechnology · doi:10.1016/j.tibtech.2016.08.011 · Cited by 426
Engineered nanomedicines with enhanced tumor penetration
Ding, J., Chen, J., Gao, L., Jiang, Z., Zhang, Y., Li, M., Xiao, Q., Lee, S. S., & Chen, X. (2019) · Nano Today · doi:10.1016/j.nantod.2019.100800 · Cited by 420
Jiang, Y., Huo, S., Mizuhara, T., Das, R., Lee, Y.-W., Hou, S., Moyano, D. F., Duncan, B., Liang, X.-J., & Rotello, V. M. (2015) · ACS Nano · doi:10.1021/acsnano.5b03521 · Cited by 401
Challenges in nanomedicine clinical translation
Metselaar, J. M., & Lammers, T. (2020) · Drug Delivery and Translational Research · doi:10.1007/s13346-020-00740-5 · Cited by 396
Current trends in drug metabolism and pharmacokinetics
Li, Y., Meng, Q., Yang, M., Liu, D., Hou, X., Tang, L., Wang, X., Lyu, Y., Chen, X., Liu, K., et al. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.10.001 · Cited by 391
Role of Nanoparticle Mechanical Properties in Cancer Drug Delivery
Hui, Y., Yi, X., Hou, F., Wibowo, D., Zhang, F., Zhao, D., Gao, H., & Zhao, C.-X. (2019) · ACS Nano · doi:10.1021/acsnano.9b03924 · Cited by 388
Nanodrugs: pharmacokinetics and safety
Onoue, S., Yamada, S., & Chan, K. (2014) · International Journal of Nanomedicine · doi:10.2147/ijn.s38378 · Cited by 382
Zhou, S.-F., Xue, C. C., Yu, X.-Q., Li, C., & Wang, G. (2007) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e31815c16f5 · Cited by 375
Dai, Q., Walkey, C., & Chan, W. C. W. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201309464 · Cited by 371
Vinarov, Z., Abdallah, M., Agundez, J. A. G., Allegaert, K., Basit, A. W., Braeckmans, M., Ceulemans, J., Corsetti, M., Griffin, B. T., Grimm, M., et al. (2021) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2021.105812 · Cited by 359
Kumthekar, P., Ko, C. H., Paunesku, T., Dixit, K., Sonabend, A. M., Bloch, O., Tate, M., Schwartz, M., Zuckerman, L., Lezon, R., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abb3945 · Cited by 345
Targeting the Tumor Microenvironment for Cancer Therapy
Sounni, N. E., & Noel, A. (2013) · Clinical Chemistry · doi:10.1373/clinchem.2012.185363 · Cited by 344
Fabrication of Corona-Free Nanoparticles with Tunable Hydrophobicity
Moyano, D. F., Saha, K., Prakash, G., Yan, B., Kong, H., Yazdani, M., & Rotello, V. M. (2014) · ACS Nano · doi:10.1021/nn5006478 · Cited by 331
Roger, E., Lagarce, F., Garcion, E., & Benoit, J.-P. (2010) · Nanomedicine · doi:10.2217/nnm.09.110 · Cited by 324
Progress, challenges, and future of nanomedicine
Zhang, C., Yan, L., Wang, X., Zhu, S., Chen, C., Gu, Z., & Zhao, Y. (2020) · Nano Today · doi:10.1016/j.nantod.2020.101008 · Cited by 318
Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance
Bar-Zeev, M., Livney, Y. D., & Assaraf, Y. G. (2017) · Drug Resistance Updates · doi:10.1016/j.drup.2017.05.002 · Cited by 314
Personalized protein corona on nanoparticles and its clinical implications
Corbo, C., Molinaro, R., Tabatabaei, M., Farokhzad, O. C., & Mahmoudi, M. (2017) · Biomaterials Science · doi:10.1039/c6bm00921b · Cited by 308
Tailoring nanoparticle designs to target cancer based on tumor pathophysiology
Sykes, E. A., Dai, Q., Sarsons, C. D., Chen, J., Rocheleau, J. V., Hwang, D. M., Zheng, G., Cramb, D. T., Rinker, K. D., & Chan, W. C. W. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1521265113 · Cited by 281
Han, S.-S., Li, Z.-Y., Zhu, J.-Y., Han, K., Zeng, Z.-Y., Hong, W., Li, W.-X., Jia, H.-Z., Liu, Y., Zhuo, R.-X., et al. (2015) · Small · doi:10.1002/smll.201402865 · Cited by 269
Organelle targeting: third level of drug targeting
Padh, H., & Sakhrani, N. (2013) · Drug Design, Development and Therapy · doi:10.2147/dddt.s45614 · Cited by 269
Multiplexed SNP genotyping using the QbeadTM system: a quantum dot-encoded microsphere-based assay
Xu, H. (2003) · Nucleic Acids Research · doi:10.1093/nar/gng043 · Cited by 269
A nanotherapeutic strategy to overcome chemotherapeutic resistance of cancer stem-like cells
Shen, S., Xu, X., Lin, S., Zhang, Y., Liu, H., Zhang, C., & Mo, R. (2021) · Nature Nanotechnology · doi:10.1038/s41565-020-00793-0 · Cited by 264
Application of magnetic nanoparticles in nucleic acid detection
Tang, C., He, Z., Liu, H., Xu, Y., Huang, H., Yang, G., Xiao, Z., Li, S., Liu, H., Deng, Y., et al. (2020) · Journal of Nanobiotechnology · doi:10.1186/s12951-020-00613-6 · Cited by 262
Kruse, C. R., Singh, M., Targosinski, S., Sinha, I., Sørensen, J. A., Eriksson, E., & Nuutila, K. (2017) · Wound Repair and Regeneration · doi:10.1111/wrr.12526 · Cited by 251
Absorption, distribution, metabolism, and excretion of nanocarriers in vivo and their influences
Zhang, A., Meng, K., Liu, Y., Pan, Y., Qu, W., Chen, D., & Xie, S. (2020) · Advances in Colloid and Interface Science · doi:10.1016/j.cis.2020.102261 · Cited by 246
Dendrimeric micelles for controlled drug release and targeted delivery
Ambade, A. V., Savariar, E. N., & Thayumanavan, S. (2005) · Molecular Pharmaceutics · doi:10.1021/mp050020d · Cited by 245 · cited 2×
“The functionalization of nanoparticles with ligands able to address the nanodrugs to specific cancer cells or sub-cellular sites not only reduces the side effects due to passive targeting but also promotes the uptake of the nanoparticles into the cells (Figure 4) [29].”
Interface-Driven Hybrid Materials Based on DNA-Functionalized Gold Nanoparticles
Liu, B., & Liu, J. (2019) · Matter · doi:10.1016/j.matt.2019.08.008 · Cited by 218
Cell membrane-coated nanosized active targeted drug delivery systems homing to tumor cells: A review
He, Z., Zhang, Y., & Feng, N. (2020) · Materials Science and Engineering: C · doi:10.1016/j.msec.2019.110298 · Cited by 215
Engineering patient-specific cancer immunotherapies
Scheetz, L., Park, K. S., Li, Q., Lowenstein, P. R., Castro, M. G., Schwendeman, A., & Moon, J. J. (2019) · Nature Biomedical Engineering · doi:10.1038/s41551-019-0436-x · Cited by 208
DNA Clutch Probes for Circulating Tumor DNA Analysis
Das, J., Ivanov, I., Sargent, E. H., & Kelley, S. O. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.6b05679 · Cited by 206
P-glycoprotein: Tissue Distribution, Substrates, and Functional Consequences of Genetic Variations
Cascorbi, I. (2011) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-14541-4_6 · Cited by 204
Grand challenges in nanomedicine
Wu, L.-P., Wang, D., & Li, Z. (2020) · Materials Science and Engineering: C · doi:10.1016/j.msec.2019.110302 · Cited by 203
Su, C., Liu, Y., Li, R., Wu, W., Fawcett, J. P., & Gu, J. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.06.008 · Cited by 200
Guéant-Rodriguez, R.-M., Guéant, J.-L., Debard, R., Thirion, S., Hong, L. X., Bronowicki, J.-P., Namour, F., Chabi, N. W., Sanni, A., Anello, G., et al. (2006) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn.83.3.701 · Cited by 198
Duan, J., Mansour, H. M., Zhang, Y., Deng, X., Chen, Y., Wang, J., Pan, Y., & Zhao, J. (2012) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.01.020 · Cited by 194
Chattopadhyay, N., Zastre, J., Wong, H.-L., Wu, X. Y., & Bendayan, R. (2008) · Pharmaceutical Research · doi:10.1007/s11095-008-9615-2 · Cited by 194
Dendrimer‐Functionalized Iron Oxide Nanoparticles for Specific Targeting and Imaging of Cancer Cells
Wang, S. H., Shi, X., Van Antwerp, M., Cao, Z., Swanson, S. D., Bi, X., & Baker, J. R. (2007) · Advanced Functional Materials · doi:10.1002/adfm.200601139 · Cited by 193
Kim, B., Pang, H.-B., Kang, J., Park, J.-H., Ruoslahti, E., & Sailor, M. J. (2018) · Nature Communications · doi:10.1038/s41467-018-04390-7 · Cited by 192
Rao, L., Yu, G., Meng, Q., Bu, L., Tian, R., Lin, L., Deng, H., Yang, W., Zan, M., Ding, J., et al. (2019) · Advanced Functional Materials · doi:10.1002/adfm.201905671 · Cited by 190
Balestrini, S., & Sisodiya, S. M. (2017) · Neuroscience Letters · doi:10.1016/j.neulet.2017.01.014 · Cited by 186
Physiologically Based Pharmacokinetic Modeling of Nanoparticles
Yuan, D., He, H., Wu, Y., Fan, J., & Cao, Y. (2019) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2018.10.037 · Cited by 186
Ahmad, A., Khan, F., Mishra, R. K., & Khan, R. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00511 · Cited by 186
SMA–doxorubicin, a new polymeric micellar drug for effective targeting to solid tumours
Greish, K., Sawa, T., Fang, J., Akaike, T., & Maeda, H. (2004) · Journal of Controlled Release · doi:10.1016/j.jconrel.2004.03.027 · Cited by 183
Self-citationGupta, T., Singh, J., Kaur, S., Sandhu, S., Singh, G., & Kaur, I. P. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.00879 · Cited by 176
Gaylord, B. S., Massie, M. R., Feinstein, S. C., & Bazan, G. C. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0407578101 · Cited by 175
Arya, G., Vandana, M., Acharya, S., & Sahoo, S. K. (2011) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2011.03.009 · Cited by 174
Fusogenic Liposomes as Nanocarriers for the Delivery of Intracellular Proteins
Kube, S., Hersch, N., Naumovska, E., Gensch, T., Hendriks, J., Franzen, A., Landvogt, L., Siebrasse, J.-P., Kubitscheck, U., Hoffmann, B., et al. (2017) · Langmuir · doi:10.1021/acs.langmuir.6b04304 · Cited by 174
Singer, J. W., Baker, B., de Vries, P., Kumar, A., Shaffer, S., Vawter, E., Bolton, M., & Garzone, P. D. (2004) · Advances in experimental medicine and biology · doi:10.1007/0-306-47932-x_6 · Cited by 168
Macrophage Autophagy and Bacterial Infections
Bah, A., & Vergne, I. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01483 · Cited by 166
A SARS-CoV-2 targeted siRNA-nanoparticle therapy for COVID-19
Idris, A., Davis, A., Supramaniam, A., Acharya, D., Kelly, G., Tayyar, Y., West, N., Zhang, P., McMillan, C. L. D., Soemardy, C., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.05.004 · Cited by 164
Recent Advances in pH-Sensitive Polymeric Nanoparticles for Smart Drug Delivery in Cancer Therapy
Lim, E.-K., Chung, B. H., & Chung, S. J. (2018) · Current Drug Targets · doi:10.2174/1389450117666160602202339 · Cited by 163
The particle in the spider's web: transport through biological hydrogels
Witten, J. J., & Ribbeck, K. (2017) · Nanoscale · doi:10.1039/c6nr09736g · Cited by 163
Li, H., Zhang, P., Luo, J., Hu, D., Huang, Y., Zhang, Z.-R., Fu, Y., & Gong, T. (2019) · ACS Nano · doi:10.1021/acsnano.9b04166 · Cited by 162
Subcellular Performance of Nanoparticles in Cancer Therapy
Liu, C., Han, Y., Kankala, R. K., Wang, S., & Chen, A. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s226186 · Cited by 160
Zhang, Z., Gao, F., Bu, H., Xiao, J., & Li, Y. (2012) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2011.08.016 · Cited by 159
Improved oral bioavailability of alendronate via the mucoadhesive liposomal delivery system
Han, H., Shin, H., & Ha, D. H. (2012) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2012.04.002 · Cited by 158
Gromnicova, R., Davies, H. A., Sreekanthreddy, P., Romero, I. A., Lund, T., Roitt, I. M., Phillips, J. B., & Male, D. K. (2013) · PLoS ONE · doi:10.1371/journal.pone.0081043 · Cited by 157
Revival of the abandoned therapeutic wortmannin by nanoparticle drug delivery
Karve, S., Werner, M. E., Sukumar, R., Cummings, N. D., Copp, J. A., Wang, E. C., Li, C., Sethi, M., Chen, R. C., Pacold, M. E., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1120508109 · Cited by 154
Qian, Y., Wang, X., Liu, Y., Li, Y., Colvin, R. A., Tong, L., Wu, S., & Chen, X. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.06.008 · Cited by 149 · cited 1×
“Moreover, mutations in proteins of the Ras family, such as KRAS, are associated with a heightened macropinocytotic activity that comes up with cell proliferation and sustained ATP accumulation and consumption in the tumor microenvironment [113].”
Paclitaxel poliglumex (XYOTAX; CT-2103): an intracellularly targeted taxane
Singer, J. W., Shaffer, S. A., Baker, B., Bernareggi, A., Stromatt, S. C., Nienstedt, D., & Besman, M. (2005) · Anti-Cancer Drugs · doi:10.1097/00001813-200503000-00003 · Cited by 149
Jiang, J., Yang, S.-J., Wang, J., Yang, L., Xu, Z.-Z., Yang, T., Liu, X.-Y., & Zhang, Q. (2010) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2010.06.011 · Cited by 149
Ren, J., Cai, R., Wang, J., Ghouri, M. D., Baimanov, D., Liu, Y., Yin, D., Liu, Y., Miao, Q., Zhao, Y., et al. (2019) · Nano Letters · doi:10.1021/acs.nanolett.9b01774 · Cited by 145
Samimi, S., Ardestani, M. S., & Dorkoosh, F. A. (2020) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2020.102287 · Cited by 142
Delivery of drugs and macromolecules to the mitochondria for cancer therapy
Lu, P., Bruno, B. J., Rabenau, M., & Lim, C. S. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.10.023 · Cited by 135
Targeted delivery of doxorubicin to mitochondria using mesoporous silica nanoparticle nanocarriers
Qu, Q., Ma, X., & Zhao, Y. (2015) · Nanoscale · doi:10.1039/c5nr05139h · Cited by 135
Folate Receptor α Associated With Triple-Negative Breast Cancer and Poor Prognosis
Zhang, Z., Wang, J., Tacha, D., Li, P., Bremer, R. E., Chen, H., Wei, B., Xiao, X., Da, J., Skinner, K. A., et al. (2013) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2013-0309-oa · Cited by 128
Yu, Z., Ni, M., Xiong, M., Zhang, X., Cai, G., Chen, H., & Zeng, Q. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s78498 · Cited by 127
Livraghi-Butrico, A., Grubb, B. R., Wilkinson, K. J., Volmer, A. S., Burns, K. A., Evans, C. M., O’Neal, W. K., & Boucher, R. C. (2016) · Mucosal Immunology · doi:10.1038/mi.2016.63 · Cited by 126
Active Cellular and Subcellular Targeting of Nanoparticles for Drug Delivery
Nag, O. K., & Delehanty, J. B. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11100543 · Cited by 121
Revealing macropinocytosis using nanoparticles
Means, N., Elechalawar, C. K., Chen, W. R., Bhattacharya, R., & Mukherjee, P. (2021) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2021.100993 · Cited by 119
Triggered nanoparticles as therapeutics
Kim, C. S., Duncan, B., Creran, B., & Rotello, V. M. (2013) · Nano Today · doi:10.1016/j.nantod.2013.07.004 · Cited by 115
Sapra, P., Moase, E. H., Ma, J., & Allen, T. M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0041 · Cited by 114
PXR: a center of transcriptional regulation in cancer
Xing, Y., Yan, J., & Niu, Y. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.06.012 · Cited by 114
New clinical trial designs in the era of precision medicine
Garralda, E., Dienstmann, R., Piris‐Giménez, A., Braña, I., Rodon, J. A., & Tabernero, J. M. (2019) · Molecular Oncology · doi:10.1002/1878-0261.12465 · Cited by 110
Nanoparticles for Targeted Drug Delivery to Cancer Stem Cells: A Review of Recent Advances
Ertaş, Y. N., Dorcheh, K. A., Akbari, A., & Jabbari, E. (2021) · Nanomaterials · doi:10.3390/nano11071755 · Cited by 103
Tariq, M., Alam, A., Singh, A. T., Iqbal, Z., Panda, A. K., & Talegaonkar, S. (2015) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2015.02.043 · Cited by 100
Polycarbonate-based ultra-pH sensitive nanoparticles improve therapeutic window
Wang, X., Wilhelm, J., Li, W., Li, S., Wang, Z., Huang, G., Wang, J., Tang, H., Khorsandi, S., Sun, Z., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19651-7 · Cited by 99
Organelle targeting: third level of drug targeting
Sakhrani, N., & Padh, H. (2013) · Dove Medical Press (Taylor and Francis Group) · Cited by 99
Silver nanoparticle-embedded graphene oxide-methotrexate for targeted cancer treatment
Thapa, R. K., Kim, J. H., Jeong, J., Shin, B. S., Choi, H., Yong, C. S., & Kim, J. O. (2017) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2017.02.012 · Cited by 97
Macropinocytosis Exploitation by Cancers and Cancer Therapeutics
Ha, K. D., Bidlingmaier, S. M., & Liu, B. (2016) · Frontiers in Physiology · doi:10.3389/fphys.2016.00381 · Cited by 95
Greish, K. F. (2011) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2011.11.010 · Cited by 93
Self-citationFrom Antisense RNA to RNA Modification: Therapeutic Potential of RNA-Based Technologies
Adachi, H., Hengesbach, M., Yu, Y., & Morais, P. (2021) · Biomedicines · doi:10.3390/biomedicines9050550 · Cited by 92
Juan-Carlos, P.-D. M., Perla-Lidia, P.-P., Stephanie-Talia, M.-M., Arellano-Mendoza, M. G., & Espíndola, L. M. T. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06155-w · Cited by 91
DNA biosensors based on water-soluble conjugated polymers
Liu, X., Fan, Q., & Huang, W. (2010) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2010.09.025 · Cited by 89
Cui, T., Zhang, S., & Sun, H. (2017) · Oncology Reports · doi:10.3892/or.2017.5345 · Cited by 88
Patil, Y. P., Amitay, Y., Ohana, P., Shmeeda, H., & Gabizón, A. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.01.039 · Cited by 87
Glucose is a key driver for GLUT1-mediated nanoparticles internalization in breast cancer cells
Venturelli, L., Nappini, S., Bulfoni, M., Gianfranceschi, G., Zilio, S. D., Coceano, G., Ben, F. D., Turetta, M., Scoles, G., Vaccari, L., et al. (2016) · Scientific Reports · doi:10.1038/srep21629 · Cited by 87
Detection of TP53 mutation using a portable surface plasmon resonance DNA-based biosensor
Jiang, T., Minunni, M., Wilson, P., et al. (2004) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2004.08.040 · Cited by 86
Estrogen modulation of osteoclast lysosomal enzyme secretion
Kremer, M., Judd, J., Rifkin, B. R., Auszmann, J. M., & Oursler, M. J. (1995) · Journal of Cellular Biochemistry · doi:10.1002/jcb.240570211 · Cited by 83
Targeting cancer stem cells by using the nanoparticles
An, S. S. A., Jang, G.-B., Lee, H., Hong, I., & Nam, J. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s88310 · Cited by 74
Luo, J., Gong, T., & Ma, L. (2020) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2020.116887 · Cited by 72
Ciaffaglione, V., Modica, M. N., Pittalà, V., Romeo, G., Salerno, L., & Intagliata, S. (2021) · ChemMedChem · doi:10.1002/cmdc.202100473 · Cited by 72
Self-citationSabra, S. A., Sheweita, S. A., Haroun, M., Ragab, D., Demellawy, M. E., Xia, Y., Goodale, D. B., Allan, A. L., Elzoghby, A. O., & Rohani, S. (2018) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2018.11.044 · Cited by 71
Bhattacharya, S. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.02.151 · Cited by 71
Ni, W., Li, Z., Liu, Z., Ji, Y., Wu, L., Sun, S., Jian, X., & Gao, X. (2018) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2018.10.042 · Cited by 70
Special population considerations and regulatory affairs for clinical research
Grimsrud, K., Sherwin, C. M. T., Constance, J. E., Tak, C. R., Zuppa, A. F., Spigarelli, M. G., & Mihalopoulos, N. L. (2015) · Clinical Research and Regulatory Affairs · doi:10.3109/10601333.2015.1001900 · Cited by 69
Drug Synergy of Tenofovir and Nanoparticle-Based Antiretrovirals for HIV Prophylaxis
Chaowanachan, T., Krogstad, E. A., Ball, C. S., & Woodrow, K. A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061416 · Cited by 68
Zhao, G., Huang, J., Xue, K., Si, L., & Gao, L. (2013) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2013.08.016 · Cited by 68
Advanced targeted nanomedicine
Arachchige, M. C. M., Reshetnyak, Y. K., & Andreev, O. A. (2015) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2015.01.009 · Cited by 68
BRCA mutations in the manifestation and treatment of ovarian cancer
Pan, Z., & Xie, X. (2017) · Oncotarget · doi:10.18632/oncotarget.18280 · Cited by 68
Tyrosine kinase inhibitor conjugated quantum dots for non-small cell lung cancer (NSCLC) treatment
Kulkarni, N. S., Parvathaneni, V., Shukla, S. K., Barasa, L., Perron, J. C., Yoganathan, S., Muth, A., & Gupta, V. (2019) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2019.03.026 · Cited by 68
Chemotherapy for Patients with BRCA1 and BRCA2 –Mutated Ovarian Cancer: Same or Different?
Tan, D. S. P., & Kaye, S. B. (2015) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2015.35.114 · Cited by 67
MicroRNA regulation of endothelial TREX1 reprograms the tumour microenvironment
Wilson, R., Espinosa‐Díez, C., Kanner, N., Chatterjee, N., Ruhl, R. A., Hipfinger, C., Advani, S. J., Li, J., Khan, O. F., Franovic, A., et al. (2016) · Nature Communications · doi:10.1038/ncomms13597 · Cited by 67
Gaio, E., Conte, C., Esposito, D., Reddi, E., Quaglia, F., & Moret, F. (2020) · Cancers · doi:10.3390/cancers12020278 · Cited by 66
Marslin, G., Sheeba, C. J., Kalaichelvan, V. K., Manavalan, R., Reddy, P. N., & Franklin, G. (2009) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2009.1075 · Cited by 64
Physiologically Based Pharmacokinetic Model for Long-Circulating Inorganic Nanoparticles
Liang, X., Wang, H., Grice, J. E., Li, L., Liu, X., Xu, Z. P., & Roberts, M. S. (2016) · Nano Letters · doi:10.1021/acs.nanolett.5b03854 · Cited by 64
Riley, R., Dang, M. N., Billingsley, M. M., Abraham, B., Gundlach, L., & Day, E. S. (2018) · Nano Letters · doi:10.1021/acs.nanolett.8b00681 · Cited by 64
Clinical trial design: Past, present, and future in the context of big data and precision medicine
Li, A., & Bergan, R. C. (2020) · Cancer · doi:10.1002/cncr.33205 · Cited by 64
Corradini, R., Feriotto, G., Sforza, S., Marchelli, R., & Gambari, R. (2003) · Journal of Molecular Recognition · doi:10.1002/jmr.646 · Cited by 62
Sharma, S., Verma, A., Singh, J., Teja, B. V., Mittapelly, N., Pandey, G., Urandur, S., Shukla, R. P., Konwar, R., & Mishra, P. R. (2016) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6b08958 · Cited by 62
Wang, M., Liang, Y., Zhang, Z., Ren, G., Liu, Y., Wu, S., & Shen, J. (2019) · Analytica Chimica Acta · doi:10.1016/j.aca.2019.08.035 · Cited by 61
Pandey, S. K., Patel, D. K., Maurya, A. K., Thakur, R. K., Mishra, D. P., Vinayak, M., Haldar, C., & Maiti, P. (2016) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2016.04.065 · Cited by 60
Chemically Designed Nanoscale Materials for Controlling Cellular Processes
Debnath, K., Pal, S., & Jana, N. R. (2021) · Accounts of Chemical Research · doi:10.1021/acs.accounts.1c00215 · Cited by 59
Difficulties and challenges in the development of precision medicine
Liu, X., Luo, X., Jiang, C., & Zhao, H. (2019) · Clinical Genetics · doi:10.1111/cge.13511 · Cited by 58
Curcumin–Copper Complex Nanoparticles for the Management of Triple-Negative Breast Cancer
Greish, K. F., Pittalà, V., Taurin, S., Taha, S., Bahman, F., Mathur, A., Jasim, A. A., Mohammed, F., El-Deeb, I. M., Fredericks, S., et al. (2018) · Nanomaterials · doi:10.3390/nano8110884 · Cited by 56
Self-citationLiu, Y., Jiang, Z., Hou, X., Xie, X., Shi, J., Shen, J., He, Y., Wang, Z., & Feng, N. (2019) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2019.102075 · Cited by 56
Saroj, S., & Rajput, S. (2018) · Drug Development and Industrial Pharmacy · doi:10.1080/03639045.2018.1438467 · Cited by 55
Lababidi, N., Montefusco-Pereira, C. V., Carvalho‐Wodarz, C. D. S., Lehr, C., & Schneider, M. (2020) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2020.10.010 · Cited by 53
Depondt, C., Godard, P., Espel, R. S., Cruz, A. L. D., Lienard, P., & Pandolfo, M. (2011) · European Journal of Neurology · doi:10.1111/j.1468-1331.2011.03361.x · Cited by 51
Adenosine conjugated lipidic nanoparticles for enhanced tumor targeting
Swami, R., Singh, I. P., Jeengar, M. K., et al. (2015) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2015.03.065 · Cited by 51
Shi, M., Zheng, J., Tan, Y., Tan, G., Li, J., Li, Y., Li, X., Zhou, Z., & Yang, R. (2015) · Analytical Chemistry · doi:10.1021/ac504000p · Cited by 51
Sauraj, Kumar, V., Kumar, B., Deeba, F., Bano, S., Kulshreshtha, A., Gopinath, P., & Negi, Y. S. (2019) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2019.01.101 · Cited by 51
Zhang, Z., Cheng, W., Pan, Y., & Jia, L. (2019) · Journal of Materials Chemistry B · doi:10.1039/c9tb02284h · Cited by 51
Zhang, R., Dong, K., Wang, Z., Miao, R., Lu, W., & Wu, X. Y. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13081261 · Cited by 51
Mukhtar, M., Sargazi, S., Barani, M., Madry, H., Rahdar, A., & Cucchiarini, M. (2021) · Nanomaterials · doi:10.3390/nano11061384 · Cited by 50
Precision Medicine Clinical Trials: Defining New Treatment Strategies
Heckman‐Stoddard, B. M., & Smith, J. J. (2014) · Seminars in Oncology Nursing · doi:10.1016/j.soncn.2014.03.004 · Cited by 49
Tyrosine Kinase Inhibitor Gold Nanoconjugates for the Treatment of Non-Small Cell Lung Cancer
Cryer, A. M., Chan, C. H., Eftychidou, A., Maksoudian, C., Mahesh, M., Tetley, T. D., Spivey, A. C., & Thorley, A. J. (2019) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b02986 · Cited by 47
Plasmonics nanoprobes: detection of single-nucleotide polymorphisms in the breast cancer BRCA1 gene
Wabuyele, M. B., Yan, F., & Vo‐Dinh, T. (2010) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-010-3992-1 · Cited by 44
Melamed, J. R., Ioele, S. A., Hannum, A. J., Ullman, V. M., & Day, E. S. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00707 · Cited by 44
Delivery of Orally Administered Digestible Antibodies Using Nanoparticles
Tashima, T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073349 · Cited by 44
Zan, Y., Dai, Z., Liang, L., et al. (2019) · Drug Delivery · doi:10.1080/10717544.2019.1654040 · Cited by 43
Austin-Zimmerman, I., Wrońska, M., Wang, B., Irizar, H., Thygesen, J. H., Bhat, A., Denaxas, S., Fatemifar, G., Finan, C., Harju‐Seppänen, J., et al. (2021) · Genes · doi:10.3390/genes12111758 · Cited by 43
The Potential Role of Sildenafil in CancerManagement Through EPR Augmentation
Haider, M., Elsherbeny, A., Pittalà, V., Fallica, A. N., Alghamdi, M. A., & Greish, K. (2021) · doi:10.20944/preprints202104.0679.v1 · Cited by 42
Self-citationPreparation and Comparison of Oral Bioavailability for Different Nano-formulations of Olaparib
Pathade, A. D., Kommineni, N., Bulbake, U., Thummar, M. M., Samanthula, G., & Khan, W. (2019) · AAPS PharmSciTech · doi:10.1208/s12249-019-1468-y · Cited by 40
Colloidal gold nanoparticle conjugates of gefitinib
Lam, A. T. N., Yoon, J., Ganbold, E., Singh, D. K., Kim, D., Cho, K.-H., Lee, S. Y., Choo, J., Lee, K., & Joo, S. (2014) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2014.08.021 · Cited by 39
Punfa, W., Suzuki, S., Pitchakarn, P., Yodkeeree, S., Naiki, T., Takahashi, S., & Limtrakul, P. (2014) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2014.15.21.9249 · Cited by 37
Yang, X., Wang, Y., Chen, S., Zhang, S., & Cui, C. (2021) · International Journal of Nanomedicine · doi:10.2147/ijn.s332830 · Cited by 37
Nanobiotechnology and Personalized Medicine
Jain, K. K. (2011) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-416020-0.00008-5 · Cited by 34
Genetic polymorphisms associated with antiepileptic metabolism
Orozco-Suárez, S. A. (2014) · Frontiers in Bioscience-Elite · doi:10.2741/e713 · Cited by 34
Nanocarriers Protecting Toward an Intestinal pre-uptake Metabolism
Suchaoin, W., & Bernkop‐Schnürch, A. (2017) · Nanomedicine · doi:10.2217/nnm-2016-0331 · Cited by 34
Romana, B., Hassan, M. M., Sonvico, F., Pereira, G. G., Mason, A. F., Thordarson, P., Bremmell, K. E., Barnes, T. J., & Prestidge, C. A. (2020) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2020.07.022 · Cited by 34
Voltan, R., Secchiero, P., Ruozi, B., Forni, F., Agostinis, C., Caruso, L., Vandelli, M. A., & Zauli, G. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0015 · Cited by 33
Chen, S., Liang, Q., Liu, E., Yu, Z., Sun, L., Ye, J., Shin, M. C., Wang, J., & He, H. (2017) · Journal of Materials Chemistry B · doi:10.1039/c7tb00040e · Cited by 31
García-Garrido, E., Cordani, M., & Somoza, Á. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13122067 · Cited by 29
Yu, M., Han, S., Kou, Z., Dai, J., Liu, J., Wei, C., Li, Y., Jiang, L., & Sun, Y. (2017) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2017.1307215 · Cited by 28
Graphene quantum dots decorated with imatinib for leukemia treatment
Félix, D. M., Alencar, L. M. R., de Menezes, F. D., Midlej, V. D. V. P., Aguiar, L., Piperni, S. G., Zhang, J., Liu, Y., Ricci‐Júnior, E., Alexis, F., et al. (2020) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2020.102117 · Cited by 28
Hsu, F., Liu, H.-S., Ali, A., Tsai, P., Kao, Y. J., Lu, C., Huang, H., & Chen, C. (2018) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2018.01.010 · Cited by 27
A combination of sorafenib and nilotinib reduces the growth of castrate-resistant prostate cancer
Taurin, S., Archibald, M., Pritchard, T., Nehoff, H. L., Rosengren, R. J., & Greish, K. F. (2016) · International Journal of Nanomedicine · doi:10.2147/ijn.s97286 · Cited by 21
Self-citationMcGrath, S., Peabody, A. E., Walton, D., & Walton, N. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.663014 · Cited by 21
Lapitan, L. D., Guo, Y., & Zhou, D. (2015) · The Analyst · doi:10.1039/c4an02304h · Cited by 19
Salerno, L., Vanella, L., Sorrenti, V., Consoli, V., Ciaffaglione, V., Fallica, A. N., Canale, V., Zajdel, P., Pignatello, R., & Intagliata, S. (2021) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2021.1928111 · Cited by 18
Self-citationAugmented Inhibition of CYP3A4 in Human Primary Hepatocytes by Ritonavir Solid Drug Nanoparticles
Martin, P., Giardiello, M., McDonald, T. O., Smith, D., Siccardi, M., Rannard, S. P., & Owen, A. (2015) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00204 · Cited by 17
Adeli, M., Ashiri, M., Chegeni, B. K., et al. (2013) · Journal of the Iranian Chemical Society · doi:10.1007/s13738-012-0203-3 · Cited by 17
Cited by
The Bioavailability of Drugs—The Current State of Knowledge
Stielow, M., Witczyńska, A., Kubryń, N., Fijałkowski, Ł., Nowaczyk, J., & Nowaczyk, A. (2023) · Molecules · doi:10.3390/molecules28248038 · Cited by 391
Desai, N., Rana, D., Patel, M., Bajwa, N., Prasad, R., & Vora, L. K. (2025) · Small · doi:10.1002/smll.202502315 · Cited by 295
Clinical translation of nanomedicines for brain diseases: Current challenges and future directions
Wang, G., Wang, N., Xia, X., Ismail, M., & Shi, B. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114426 · Cited by 33
Metadata
- Authors
- Alghamdi, M. A., Fallica, A. N., Virzì, N., Kesharwani, P., Pittalà, V., & Greish, K.
- Venue
- Journal of Personalized Medicine
- Publisher
- MDPI AG
- Published
- 2022-04-22
- Volume
- 12
- Issue
- 5
- Pages
- 673
- ISSN
- 2075-4426 (ISSN-L)
- OpenAlex
- W4224314779
- Cited by
- 284
- References
- 206
- FWCI
- 11.40
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.